InVivo Therapeutics Holdings Corporation
NVIVNASDAQHealthcare
$0.32
$-0.17(-34.28%)
Market Cap$995918
P/E Ratio—
52W High$2.4
52W Low$0.22
InVivo Therapeutics Holdings Corporation (NVIV) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NVIV · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 8, 2023EPS Actual
-$0.87
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 8, 2023
After Market Close
NVIV reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2024 | Feb 14, 2024 | — | — | — | — | — | — |
| — Q4 FY2023 | Nov 8, 2023 | — | -$0.87 | — | — | — | — |
| — Q3 FY2023 | Aug 9, 2023 | — | -$1.97 | — | — | — | — |
| — Q2 FY2023 | Jun 27, 2023 | — | -$1.94 | — | — | — | — |
| — Q1 FY2023 | Mar 13, 2023 | — | -$2.25 | — | — | — | — |
| — Q4 FY2022 | Nov 7, 2022 | — | -$1.98 | — | — | — | — |
| — Q3 FY2022 | Aug 8, 2022 | — | -$1.97 | — | — | — | — |
| — Q2 FY2022 | May 10, 2022 | — | -$1.94 | — | — | — | — |
Q1 FY2024
Feb 14, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 8, 2023
EPS Actual
-$0.87
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 9, 2023
EPS Actual
-$1.97
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2023
Jun 27, 2023
EPS Actual
-$1.94
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2023
Mar 13, 2023
EPS Actual
-$2.25
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2022
Nov 7, 2022
EPS Actual
-$1.98
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2022
Aug 8, 2022
EPS Actual
-$1.97
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2022
May 10, 2022
EPS Actual
-$1.94
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 0 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 0 |
| Q1 FY2024 | $1.57 | $1.57 | $1.57 | 0 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 0 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 0 |
| Q2 FY2023 | $1.19 | $1.19 | $1.19 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2023 | Nov 8, 2023 | — | $0.87 | $0.88 | +0.57% |
| — Q3 FY2023 | Aug 9, 2023 | — | $1.38 | $1.35 | -2.17% |
| — Q2 FY2023 | Jun 27, 2023 | — | $1.34 | $1.30 | -2.99% |
| — Q1 FY2023 | Mar 13, 2023 | — | $0.99 | $1.00 | +1.01% |
| — Q4 FY2022 | Nov 7, 2022 | — | $2.20 | $2.22 | +0.91% |
| — Q3 FY2022 | Aug 8, 2022 | — | $8.96 | $8.63 | -3.68% |
| — Q2 FY2022 | May 10, 2022 | — | $4.34 | $4.13 | -4.84% |
| — Q1 FY2022 | Mar 7, 2022 | — | $7.25 | $7.25 | +0.00% |
Q4 FY2023+0.57%
Report Date
Nov 8, 2023
EPS Beat/Miss
—
Price Before
$0.87
Price After
$0.88
Q3 FY2023-2.17%
Report Date
Aug 9, 2023
EPS Beat/Miss
—
Price Before
$1.38
Price After
$1.35
Q2 FY2023-2.99%
Report Date
Jun 27, 2023
EPS Beat/Miss
—
Price Before
$1.34
Price After
$1.30
Q1 FY2023+1.01%
Report Date
Mar 13, 2023
EPS Beat/Miss
—
Price Before
$0.99
Price After
$1.00
Q4 FY2022+0.91%
Report Date
Nov 7, 2022
EPS Beat/Miss
—
Price Before
$2.20
Price After
$2.22
Q3 FY2022-3.68%
Report Date
Aug 8, 2022
EPS Beat/Miss
—
Price Before
$8.96
Price After
$8.63
Q2 FY2022-4.84%
Report Date
May 10, 2022
EPS Beat/Miss
—
Price Before
$4.34
Price After
$4.13
Q1 FY2022+0.00%
Report Date
Mar 7, 2022
EPS Beat/Miss
—
Price Before
$7.25
Price After
$7.25
Beat Rate0 / 8 quarters
Largest Move-4.84% (Q2 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NVIV ends December
InVivo Therapeutics Holdings Corporation (NVIV) most recently reported earnings on November 8, 2023 for Q4 FY2023, posting EPS of $-0.87 (in line with the analyst consensus of —). The next NVIV earnings date is expected around September 1, 2026.
Each quarter, investors track NVIV earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NVIV revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NVIV's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NVIV earnings · 4 questionsInVivo Therapeutics Holdings Corporation's next earnings report is expected around September 1, 2026. NVIV typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NVIV historically reports after market close (AMC).
NVIV earnings datewhen is NVIV earningsNVIV next earnings datewhen does NVIV report earningsNVIV earnings calendar
▸ Source: FMP · InVivo Therapeutics Holdings Corporation SEC filings · US GAAP · InVivo Therapeutics Holdings Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026